Last updated January 19th 2017

January 8, 2017 | Clal Biotechnology Industries Ltd. announced today that Neon Therapeutics had completed a $70 million financing round. Following the round, Clal Biotechnology will own 5% of US company Neon. The round was led by Partner Fund Management, together with Inbio, Wellington, Fidelity Ventures, and Nextech Invest. Previous investors Third Rock Ventures and Access Industries also took part. Neon has begun a trial of a vaccination against malaria. Clal Biotechnoloigy was founded in 1998 and is based out of Ramat Gan, Israel.